Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
- Author:
Marco FOCACCIA
1
;
Marco GAMBAROTTI
;
Rossella HAKIM
;
Anna PAIOLI
;
Marilena CESARI
;
Benedetta SPAZZOLI
;
Paolo SPINNATO
;
Davide DONATI
;
Michele ROCCA
;
Alessandra LONGHI
Author Information
- Publication Type:Case Report
- From:Cancer Research and Treatment 2021;53(1):279-282
- CountryRepublic of Korea
- Language:English
- Abstract: Chondroblastoma is a rare benign chondrogenic tumor that occurs in skeletally immature patients between ages 10 and 20 years old. In literature are reported few cases of lung metastases, mainly occurred after surgery or local recurrences. There is no evidence on the pathogenesis of lung metastasis, as well as pulmonary disease course. Few treatments for metastases with aggressive behavior were based on chemotherapy regimen employed in other sarcoma with no results or not satisfying ones. Denosumab is approved for treatment of giant cell tumors and it is under investigation for other giant cell-rich bone tumors. Here, we report a case of a 16-year-old male chondroblastoma of the left humerus with bilateral lung metastases at presentation and progressing during follow-up, treated with denosumab for almost 2 years. We confirm that denosumab treatment can be effective in controlling chondroblastoma metastasis and it has been a safe procedure in an adolescent patient.
